pimivalimab

DRUG2 trials

Sponsors

Jounce Therapeutics, Inc.

Conditions

CancerNSCLC

Phase 1

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

CompletedNCT04669899

Jounce Therapeutics, Inc.Cancer

Start: 2021-01-12End: 2023-11-28Updated: 2024-04-09

Phase 2

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

TerminatedNCT04549025

Jounce Therapeutics, Inc.NSCLC

Start: 2020-10-19End: 2024-04-25Updated: 2024-05-22

Related Papers

Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.

Journal of Clinical Oncology2024-06-011 citations

172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors

Immuno-Oncology Technology2022-12-011 citations

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

Journal of Clinical Oncology2021-05-206 citations

Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).

Journal of Clinical Oncology2021-05-202 citations